The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.

doi:10.1158/2159-8290.CD-21-1136

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.

Cancer discovery - 2 May 2022

Berlanga Pablo, Pierron Gaelle, Lacroix Ludovic, Chicard Mathieu, Adam de Beaumais Tiphaine, Marchais Antonin, Harttrampf Anne C, Iddir Yasmine, Larive Alicia, Soriano Fernandez Aroa, Hezam Imene, Chevassus Cecile, Bernard Virginie, Cotteret Sophie, Scoazec Jean-Yves, Gauthier Arnaud, Abbou Samuel, Corradini Nadege, André Nicolas, Aerts Isabelle, Thebaud Estelle, Casanova Michela, Owens Cormac, Hladun-Alvaro Raquel, Michiels Stefan, Delattre Olivier, Vassal Gilles, Schleiermacher Gudrun, Geoerger Birgit

Abstract excerpt

ABSTRACT: MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma

Share to Cell-Free Nucleic Acids

Share to Child

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Recurrence, Local

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 35292802
DOI: 10.1158/2159-8290.CD-21-1136
PMCID: PMC9394403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.PMID 35292802Read ↗

Pediatric Patient-Derived-Xenograft development in MAPPYACTS – international pediatric cancer precision medicine trial in relapsed and refractory tumorsSemantic proximity Read ↗

Functional Precision Medicine Enhances Clinical Outcomes of Relapsed/Refractory Pediatric and Adolescent Cancer PatientsSemantic proximity Read ↗

Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent CancerSemantic proximity Read ↗

Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.Semantic proximity Read ↗

Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experienceSemantic proximity Read ↗

Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.Semantic proximity Read ↗

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trialSemantic proximity Read ↗

Genomics-Driven Precision Medicine in Pediatric Solid TumorsSemantic proximity Read ↗

MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.Semantic proximity Read ↗

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.Semantic proximity Read ↗

An update on genomic-guided therapies for pediatric solid tumors.Semantic proximity Read ↗

Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.